Suppr超能文献

替尔泊肽通过选择性地降低啮齿动物对脂肪的偏好来抑制美味食物的摄入。

Tirzepatide suppresses palatable food intake by selectively reducing preference for fat in rodents.

机构信息

Department of Psychiatry, University of Pennsylvania, Philadelphia, Pennsylvania.

Diabetes, Obesity and Complications, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana.

出版信息

Diabetes Obes Metab. 2023 Jan;25(1):56-67. doi: 10.1111/dom.14843. Epub 2022 Sep 12.

Abstract

AIM

To investigate the role of glucose-dependent insulinotropic polypeptide receptor (GIPR) agonists alone or combined with glucagon-like peptide-1 receptor (GLP-1R) agonists to regulate palatable food intake and the role of specific macronutrients in these preferences.

METHODS

To understand this regulation, we treated mice and rats on several choice diet paradigms of chow and a palatable food option with individual or dual GIPR and GLP-1R agonists.

RESULTS

In mice, the dual agonist tirzepatide suppressed total caloric intake, while promoting the intake of chow over a high fat/sucrose diet. Surprisingly, GIPR agonism alone did not alter food choice. The food intake shift observed with tirzepatide in wild-type mice was completely absent in GLP-1R knockout mice, suggesting that GIPR signalling does not regulate food preference. Tirzepatide also selectively suppressed the intake of palatable food but not chow in a rat two-diet choice model. This suppression was specific to lipids, as GLP-1R agonist and dual agonist treatment in rats on a choice paradigm assessing individual palatable macronutrients robustly inhibited the intake of Crisco (lipid) without decreasing the intake of a sucrose (carbohydrate) solution.

CONCLUSIONS

Decreasing preference for high-caloric, high-fat foods is a powerful action of GLP-1R and dual GIPR/GLP-1R agonist therapeutics, which may contribute to the weight loss success of these drugs.

摘要

目的

研究葡萄糖依赖性胰岛素促分泌多肽受体(GIPR)激动剂单独或与胰高血糖素样肽-1 受体(GLP-1R)激动剂联合调节美味食物摄入的作用,以及特定宏量营养素在这些偏好中的作用。

方法

为了理解这种调节作用,我们在几种选择饮食范式中,用单独或双重 GIPR 和 GLP-1R 激动剂处理小鼠和大鼠,包括标准饮食和美味食物选择。

结果

在小鼠中,双重激动剂替西帕肽抑制总热量摄入,同时促进对高脂肪/蔗糖饮食的摄入。令人惊讶的是,GIPR 激动剂单独使用不会改变食物选择。在野生型小鼠中观察到的替西帕肽引起的食物摄入转移在 GLP-1R 敲除小鼠中完全缺失,表明 GIPR 信号不调节食物偏好。替西帕肽还选择性地抑制美味食物的摄入,但在大鼠的两种饮食选择模型中不会减少标准饮食的摄入。这种抑制是特定于脂类的,因为 GLP-1R 激动剂和双重激动剂在评估个体美味宏量营养素的选择范式中治疗大鼠,强烈抑制 Crisco(脂质)的摄入,而不会减少蔗糖(碳水化合物)溶液的摄入。

结论

降低对高热量、高脂肪食物的偏好是 GLP-1R 和双重 GIPR/GLP-1R 激动剂治疗的强大作用,这可能有助于这些药物的减肥成功。

相似文献

1
Tirzepatide suppresses palatable food intake by selectively reducing preference for fat in rodents.
Diabetes Obes Metab. 2023 Jan;25(1):56-67. doi: 10.1111/dom.14843. Epub 2022 Sep 12.
3
Optimized GIP analogs promote body weight lowering in mice through GIPR agonism not antagonism.
Mol Metab. 2019 Feb;20:51-62. doi: 10.1016/j.molmet.2018.12.001. Epub 2018 Dec 5.
4
Glucose-dependent insulinotropic polypeptide regulates body weight and food intake via GABAergic neurons in mice.
Nat Metab. 2023 Dec;5(12):2075-2085. doi: 10.1038/s42255-023-00931-7. Epub 2023 Nov 9.
6
Discovery of a potent GIPR peptide antagonist that is effective in rodent and human systems.
Mol Metab. 2022 Dec;66:101638. doi: 10.1016/j.molmet.2022.101638. Epub 2022 Nov 15.
7
The incretin co-agonist tirzepatide requires GIPR for hormone secretion from human islets.
Nat Metab. 2023 Jun;5(6):945-954. doi: 10.1038/s42255-023-00811-0. Epub 2023 Jun 5.
9
Pharmacological antagonism of the incretin system protects against diet-induced obesity.
Mol Metab. 2020 Feb;32:44-55. doi: 10.1016/j.molmet.2019.11.018. Epub 2019 Dec 3.

引用本文的文献

1
Case Report: Amelioration of severe metabolic dysfunction-associated steatohepatitis after switching from conventional GLP-1RAs to tirzepatide.
Front Endocrinol (Lausanne). 2025 May 26;16:1501984. doi: 10.3389/fendo.2025.1501984. eCollection 2025.
2
Mechanosensation of the heart and gut elicits hypometabolism and vigilance in mice.
Nat Metab. 2025 Feb;7(2):263-275. doi: 10.1038/s42255-024-01205-6. Epub 2025 Jan 17.
3
Insights into the neurobiology of weight loss after bariatric surgery and GLP-1R agonists.
Neuropharmacology. 2025 Mar 1;265:110269. doi: 10.1016/j.neuropharm.2024.110269. Epub 2024 Dec 14.
4
Transforming obesity: The advancement of multi-receptor drugs.
Cell. 2024 Jul 25;187(15):3829-3853. doi: 10.1016/j.cell.2024.06.003.
5
Tirzepatide against obesity and insulin-resistance: pathophysiological aspects and clinical evidence.
Front Endocrinol (Lausanne). 2024 Jun 24;15:1402583. doi: 10.3389/fendo.2024.1402583. eCollection 2024.
6
GLP1-GIP receptor co-agonists: a promising evolution in the treatment of type 2 diabetes.
Acta Diabetol. 2024 Aug;61(8):941-950. doi: 10.1007/s00592-024-02300-6. Epub 2024 Jun 3.
7
Female obesity: clinical and psychological assessment toward the best treatment.
Front Endocrinol (Lausanne). 2024 May 3;15:1349794. doi: 10.3389/fendo.2024.1349794. eCollection 2024.
8
Pharmacological Advances in Incretin-Based Polyagonism: What We Know and What We Don't.
Physiology (Bethesda). 2024 May 1;39(3):142-156. doi: 10.1152/physiol.00032.2023. Epub 2024 Feb 14.
9
Poly-Agonist Pharmacotherapies for Metabolic Diseases: Hopes and New Challenges.
Drugs. 2024 Feb;84(2):127-148. doi: 10.1007/s40265-023-01982-6. Epub 2023 Dec 21.
10
Efficacy and safety of the dual GIP and GLP-1 receptor agonist tirzepatide for weight loss: a meta-analysis of randomized controlled trials.
Int J Obes (Lond). 2023 Oct;47(10):883-892. doi: 10.1038/s41366-023-01337-x. Epub 2023 Jul 17.

本文引用的文献

1
Effects of Tirzepatide, a Dual GIP and GLP-1 RA, on Lipid and Metabolite Profiles in Subjects With Type 2 Diabetes.
J Clin Endocrinol Metab. 2022 Jan 18;107(2):363-378. doi: 10.1210/clinem/dgab722.
2
GIP Receptor Agonism Attenuates GLP-1 Receptor Agonist-Induced Nausea and Emesis in Preclinical Models.
Diabetes. 2021 Nov;70(11):2545-2553. doi: 10.2337/db21-0459. Epub 2021 Aug 11.
5
Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes.
N Engl J Med. 2021 Aug 5;385(6):503-515. doi: 10.1056/NEJMoa2107519. Epub 2021 Jun 25.
7
The glucose-dependent insulinotropic polypeptide (GIP) regulates body weight and food intake via CNS-GIPR signaling.
Cell Metab. 2021 Apr 6;33(4):833-844.e5. doi: 10.1016/j.cmet.2021.01.015. Epub 2021 Feb 10.
10
Glucagon-like peptide-1 receptor co-agonists for treating metabolic disease.
Mol Metab. 2021 Apr;46:101090. doi: 10.1016/j.molmet.2020.101090. Epub 2020 Sep 25.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验